Growth and adrenal responsiveness with budesonide in young asthmatics.
Inhaled corticosteroid therapy for asthma is used increasingly from a pre-school age. Current knowledge of adverse systemic effects, however, is based on treatment of older children. Eighteen asthmatic children aged 4.5-7.4 years who had taken budesonide by Nebuhaler in doses averaging 200-1100 micrograms m-2 day-1 during the previous year were studied. Height velocities calculated over this period were no different from those of the normal population. Neither the velocities nor a modest delay in bone ages were related to budesonide dose. Every child responded normally to tetracosactrin. These young asthmatic children do not show a greater susceptibility to systemic effects from an inhaled corticosteroid than older counterparts.
Ruiz
R G
RG
Department of Child Health, King's College School of Medicine and Dentistry, London, U.K.
Price
J F
JF
D000287:Administration, Topical; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001249:Asthma / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D001827:Body Height; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D019819:Budesonide; D002648:Child; D002675:Child, Preschool; D005260:Female; D006128:Growth / Q000187:drug effects*; D006801:Humans; D006854:Hydrocortisone / Q000097:blood; D008297:Male; D011282:Pregnenediones / Q000627:therapeutic use*; D012189:Retrospective Studies
D000893:Anti-Inflammatory Agents; D001993:Bronchodilator Agents; D011282:Pregnenediones; D019819:Budesonide; D006854:Hydrocortisone